← Back to feedRead original →
VERIFIEDET Stocks·positive
Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD
AI Summary
- ·Aurobindo Pharma's shares increased following its subsidiary Lannett Company's launch of generic Advair Diskus in the US.
- ·The generic Advair Diskus is available in two strengths and is the first commercialized product from Aurobindo's inhalation pipeline.
- ·Aurobindo Pharma's stock has seen a year-to-date gain of 41.16% in 2026.